Circle Health Holdings Limited acquires CHC Healthcare Holdings Limited

Deal facts

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Announced: Not stated
Status: Completed
Sector: Healthcare
Country: United Kingdom
Consideration: Not stated

Sources

What we know

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in the United Kingdom, with the buyer operating as a UK-based organisation. The transaction involves the transfer of ownership from the target to the acquiring group, marking a consolidation of assets within the domestic market. No specific financial consideration or deal value was disclosed in the available records, and the exact date of announcement remains unreported.

The transaction has been completed, indicating that the legal and operational transfer of the business has concluded. Regulatory approvals and other standard conditions required for the deal have been satisfied to finalise the acquisition. This move represents a significant development for the healthcare landscape in the region, bringing the target company under the control of the established buyer. The deal stands as a completed strategic acquisition without further public updates on integration plans or future operational changes.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

13 Aug 2021CompletedClosed
Circle Health / BMI Healthcare: Review of undertakings
The CMA is reviewing the undertakings in lieu of a reference relating to the completed acquisition by Circle Health Holdings Limited of all the issued share capital of CHC Healthcare Holdings Limited. Administrative timetable Any revisions made to the timetable will be published on this webpage. Date Action 2 May 2024 Publish final decisions November 2021 Publish
UK CMA

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of CHC Healthcare Holdings Limited by Circle Health Holdings Limited. Both entities operate within the UK healthcare sector, and this strategic move consolidates two significant players under one roof. The deal is already done, which means the market has absorbed the news and the integration phase is now the only variable that matters. For the SME founder watching from the sidelines, this transaction highlights how scale remains a primary driver in a fragmented sector where operational efficiency and network reach are critical differentiators.

The mechanics of a domestic strategic acquisition like this often hinge on regulatory clearance from the Competition and Markets Authority before completion. Since the deal is marked as completed, we can infer that any competition concerns were either non-existent or successfully addressed during the review process. This is a vital lesson for founders planning their own exits. You must assume that a transaction of this nature will face scrutiny regarding market concentration. Preparing your data room to demonstrate that the combination will not harm consumer choice or drive up prices is not optional; it is a prerequisite for getting the deal across the line.

We think the absence of a disclosed value or currency in the public record is typical for private group acquisitions where commercial confidentiality is paramount. However, the strategic logic is evident. By bringing CHC Healthcare into the Circle Health fold, the buyer gains immediate access to new service lines or geographic footprints without the time and risk of organic growth. This approach reduces the execution risk that often plagues standalone expansion plans. The buyer has effectively bought a ready-made capability, which is often faster and more reliable than building it from scratch.

Your immediate task this week is to map your own business against the regulatory thresholds that would trigger a CMA review. Identify the specific market segments where your operations overlap with potential acquirers and prepare a one-page narrative explaining why a combination would not reduce competition. Do not wait for a buyer to ask for this; having it ready demonstrates commercial maturity and can accelerate the due diligence process significantly.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More strategic acquisition deals More from Circle Health Holdings Limited All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

11 August 2026ClearedHealthcare

Dolby Medical Home Respiratory Care Limited (Vivisol) to acquire Air Liquide Healthcare Limited’s home oxygen services business

Dolby Medical Home Respiratory Care Limited, trading as Vivisol, has agreed to acquire the home oxygen services business of Air Liquide Healthcare Limited in a strategic…

Buyer: Dolby Medical Home Respiratory Care Limited (Vivisol)
Target: Air Liquide Healthcare Limited’s home oxygen services business
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

10 August 2026Firm intentionHealthcare

RSLGH, LLC to acquire RYTHM, Inc.

RSLGH, LLC has agreed to acquire RYTHM, Inc., a healthcare company based in the United States, in a strategic acquisition valued at $109.5 million. The transaction invol…

Buyer: RSLGH, LLC
Target: RYTHM, Inc.
Deal value: USD 109,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

5 August 2026CompletedHealthcare

Ensysce Biosciences, Inc. to acquire Cy Biopharma, Inc.

Ensysce Biosciences, Inc. has agreed to acquire Cy Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 5 August 202…

Buyer: Ensysce Biosciences, Inc.
Target: Cy Biopharma, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

31 July 2026Firm intentionHealthcare

Profusa, Inc. to acquire G3 Vision Labs Inc.

Profusa, Inc. has agreed to acquire G3 Vision Labs Inc. in a strategic acquisition within the healthcare sector. The transaction involves the exchange of shares as the p…

Buyer: Profusa, Inc.
Target: G3 Vision Labs Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

28 July 2026CompletedHealthcare

Processa Pharmaceuticals, Inc. to acquire Vidya Therapeutics, Inc.

Processa Pharmaceuticals, Inc. has agreed to acquire Vidya Therapeutics, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced and…

Buyer: Processa Pharmaceuticals, Inc.
Target: Vidya Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history